First trimester screening (ETS)/PAPP-A, free beta-HCG
Material: | 2 ml serum Let whole blood coagulate fully at room temperature, centrifuge sample within 1 hour, divide serum from clot, transfer into serum transport tube and keep refrigerated until shipping. The sample should reach the laboratory within 48 hours. If other tubes with blood are taken at the same time, the whole blood has to be taken first to avoid contamination with EDTA etc. An evaluation is only possible between the 11+0 and the 13+6 week of pregnancy and with a crown-rump-length between 45 mm – 84 mm. |
Methods: | Ligandenassays → Immunfluoreszenzassay (IFA) | Reference range | Please refer to findings report. |
Indication | The first trimester screening calculates the baby’s risk of developing trisomy 21, 18 or 13 by an algorithm from the concentration of both parameters PAPP-A and free beta-HCG in the maternal blood, the nuchal translucency (measurement by ultrasound via the obstetrician), maternal age as well as additional factors such as ethnicity, smoking status etc. |
Please note | Risk assessment and evaluation are only possible in connection with the fully completed first trimester questionaire and the consent declaration in accordance with the genetic diagnostics law. A reduced kidney function (Serum-creatinine > 1,2 mg/dl) leads to a false-positive increased risk for trisomy 21. Analysis is by BRAHMS KRYPTOR via TRACE-technology. Please note that the first trimester screening has to be paid for privately. |
Accredited | ja |
More Results for the letter F
- Factor II activity (FACT01)
- Prothrombin
- Factor II mutation (FACT02)
- Prothrombin mutation G20210A
- Factor IX activity (FACT11)
- Factor V activity (FACT03)
- Factor V mutation Leiden (FACT04)
- Mutation: G1691A
- Factor VII activity (FACT05)
- Factor VIII activity (FACT06)
- Factor VIII inhibitor (FACT10)
- Factor VIII ristocetin cofactor (von Willebrand factor activity) (FACT08)
- vWF:activity
- Factor VIII von Willebrand factor antigen (FACT07)
- vWF:Ag
- Factor VIII von Willebrand multimers (FACT09)
- Factor X activity (FACT12)
- Factor XI activity (FACT13)
- Factor XII activity (FACT14)
- Hageman-Factor
- Factor XIII activity (FACT15)
- Syn.: fibrin stabilising factor
- Factor–II–activity (FAK2)
- Prothrombin
- Factor-II-mutation (FAK2GM)
- Prothrombin mutation G20210A
- Factor-IX-activity (FAK9)
- Factor-V-activity (FAK5)
- Factor-V-mutation Leiden (FAK5GM)
- Mutation: G1691A
- Factor-VII-activity (FAK7)
- Factor-VIII-activity (FAK8)
- Factor-VIII-inhibitor (FAK8IN)
- Bethesda assay
- Factor-X-activity (FAK10)
- Factor-XI-activity (FAK11)
- Factor-XII-activity (FAK12)
- Hageman factor
- Factor-XIII-activity (FAK13)
- Fibrin-stabilizing factor
- Fasciola hepatica (FASCI, FASCG)
- Common liver fluke
- Fat, total in stool (FETT1)
- Fatty acids, long-chained (LAFS)
- LCFA